Fig. 1: Elevated PILRB expression associated with poor clinical outcomes in GC patients. | Cell Death & Disease

Fig. 1: Elevated PILRB expression associated with poor clinical outcomes in GC patients.

From: PILRB potentiates the PI3K/AKT signaling pathway and reprograms cholesterol metabolism to drive gastric tumorigenesis and metastasis

Fig. 1

A TCGA database on the UALCAN website displayed that PILRB mRNA level was increased in stomach adenocarcinoma (STAD) tissues. B TCGA database on the UALCAN website revealed that PILRB expression is higher in STAD patients with advanced clinical stage compared to adjacent normal tissues. C TCGA database on the UALCAN website indicated that STAD patients with advanced lymph node metastasis had remarkably higher PILRB expression compared to adjacent normal tissues. D TCGA database on the UALCAN website illustrated that patients with high tumor grade had higher STAD expression compared to adjacent normal tissues. E, F Kaplan–Meier estimates of overall survival (E) and PF (F) in STAD patients by different PILRB protein levels (https://kmplot.com/analysis/). G PILRB mRNA levels were significantly upregulated in tumor tissues compared with paired normal tissues (n = 12). H Western blotting analysis demonstrated higher levels of PILRB protein in tumor tissues compared with paired normal tissues (n = 12). I Representative IHC images (Left) and IHC score (Right) of PILRB protein levels in tumors and paired normal tissues (n = 49). J Survival analysis of 49 patients with STAD in relation to different PILRB expression levels (P < 0.05).

Back to article page